The Dengue Vaccine Market size was valued at USD 361 million in 2021 and is expected to grow to USD 1096.48 Million by 2027 at a CAGR of 17.2% during the forecast period. As per the World Health Organization, the frequency of dengue has become significantly over ongoing many years. A larger part of the cases are asymptomatic, gentle or independent, and thus the genuine number of diseases are exceptionally under-announced. One displaying gauge demonstrates 390 million dengue infection diseases each year (95% valid span 284-528 million), of which 96 million show clinically. Dengue vaccines market report gives a comprehensive outlook of dengue vaccine market across the globe with special emphasis on key regions such as Asia-Pacific, Latin America, and Middle East & Africa (MEA) North America, and Europe. This report on global market gives historical, current, and future market sizes (US$ Mn) of product types, vaccine type, end users, and geographic regions. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, dengue vaccines market report covers newer product introductions and competition analysis with vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the dengue vaccine market report include suppliers, manufacturers, marketers, policymakers engaged in manufacturing and supply of dengue vaccine.
Key Market Developments:
In May 2019, The Food and Drug Administration approved the first vaccine against dengue fever with major restrictions.
In May 2021, Takeda’s released Phase 3 results of Dengue Vaccine Candidate (TAK-003), which Prevented 83.6% of Hospitalizations and 62.0% of Dengue Illness Overall, With No Identified Important Safety Risks Through Three Years Following Vaccination in Ongoing Pivotal TIDES Trial.